Efficacy and Safety of an Increased-dose of Dexamethasone in Patients Receiving Fosaprepitant Chemotherapy in Japan

Kumagai, Hozumi; Kusaba, Hitoshi; Okumura, Yuta; Komoda, Masato; Nakano, Michitaka; Tamura, Shingo; Uchida, Mayako; Nagata, Kenichiro; Arita, Shuji; Ariyama, Hiroshi; Takaishi, Shigeo; Akashi, Koichi; Baba, Eishi

추천

검색

자료유형: 학술저널

저자정보: Kumagai, Hozumi (Department of Hematology and Oncology, Kyushu University Hospital) Kusaba, Hitoshi (Department of Hematology and Oncology, Kyushu University Hospital) Okumura, Yuta (Department of Hematology and Oncology, Kyushu University Hospital) Komoda, Masato (Department of Hematology and Oncology, Kyushu University Hospital) Nakano, Michitaka (Department of Hematology and Oncology, Kyushu University Hospital) Tamura, Shingo (Department of Hematology and Oncology, Kyushu University Hospital) Uchida, Mayako (Department of Pharmacy, Kyushu University Hospital) Nagata, Kenichiro (Department of Pharmacy, Kyushu University Hospital) Arita, Shuji (Department of Hematology and Oncology, Kyushu University Hospital) Ariyama, Hiroshi (Department of Hematology and Oncology, Kyushu University Hospital) Takaishi, Shigeo (Center for Advanced Medical Innovation, Kyushu University) Akashi, Koichi (Department of Hematology and Oncology, Kyushu University Hospital) Baba, Eishi (Department of Comprehensive Clinical Oncology, Faculty of Medical Sciences, Kyushu University)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제15권 제1호

발행연도: 2014.1

수록면: 461 - 465 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background: Antiemetic triplet therapy including dexamethasone (DEX) is widely used for patients receiving highly emetogenic chemotherapy (HEC). In Japan, the appropriate dose of DEX has not been established for this combination. Materials and Methods: To assess the efficacy and safety of increased-dose DEX, we retrospectively examined patients receiving HEC with antiemetic triplet therapy. Results: Twenty-four patients (fosaprepitant group) were given an increased-dose of DEX (average total dose: 45.8mg), fosaprepitant, and 5-HT3 antagonist. A lower-dose of DEX (33.6mg), oral aprepitant, and 5-HT3 antagonist were administered to the other 48 patients (aprepitant group). The vomiting control rates in the fosaprepitant and aprepitant groups were 100% and 85.4% in the acute phase, and were 75.0% and 64.6% in the delayed phase. The incidences of toxicity were similar comparing the two groups. Conclusions: Triplet therapy using an increased-dose of DEX is suggested to be safe and effective for patients receiving HEC.

#Highly emetogenic chemotherapy #dexamethasone #fosaprepitant

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요